<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986986</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO</org_study_id>
    <secondary_id>Department of Defense</secondary_id>
    <nct_id>NCT00986986</nct_id>
  </id_info>
  <brief_title>Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels</brief_title>
  <official_title>Prospective Randomized Pilot Study of the Effect of Niaspan on Endothelial Function in HIV-infected Subjects With Low HDL Cholesterol Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pilot study examining the effect of extended-release niacin (Niaspan ®) on
      flow-mediated vasodilation (FMD) of the brachial artery, among human immunodeficiency virus
      (HIV)-1 infected individuals with low high density lipoprotein (HDL). Brachial artery
      diameter will be measured by high-resolution ultrasound at entry and week 12 of study. The
      primary comparisons will be change in FMD from baseline to 12 weeks within each of the two
      arms. The second specific aim will be to investigate the proportion of the effect of
      extended-release niacin on other known cardiovascular markers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low high density lipoprotein (HDL) and a lipid pattern consistent with atherogenic
      dyslipidemia are also common in the human immunodeficiency virus (HIV)infected population and
      is likely due, in large part, to the chronic inflammatory effect of HIV infection per se.
      While highly active antiretroviral therapy (HAART) and the resultant reconstitution of the
      immune system might be expected to lead to improvement in this lipid profile, studies from
      our own research as well as others clearly demonstrate that such therapy fails to fully
      correct the low HDL pattern. This coronary artery disease (CAD) risk in the HIV population is
      then further compounded by the dyslipidemic effects of various protease inhibitors and other
      antiretroviral medications used to treat HIV.

      Endothelial dysfunction is an early marker of atherosclerosis that can be determined
      non-invasively utilizing assessment of flow-mediated vasodilation (FMD) of the brachial
      artery, which may be analogous to blood flow through coronary arteries. Using this novel
      technology and HIV as a model of a chronic inflammatory state, we propose to determine if
      increasing HDL in subjects with low HDL but no LDL elevation may have potential beneficial
      effects. Our overall hypothesis for this pilot project is that increasing HDL levels in
      HIV-infected subjects with low HDL by the use of extended-release niacin over a 12 week
      period will lead to an identifiable improvement in endothelial function.

      Specific Aim 1. To compare endothelial function, measured by flow-mediated vasodilation (FMD)
      of the brachial artery, among HIV-1 infected individuals with low high density lipoprotein
      (HDL) before and after treatment with extended-release niacin (Niaspan ®)

        -  Conduct a prospective randomized 12-week clinical trial on HIV-1 infected individuals
           with low HDL and normal low density lipoprotein levels who plan to continue their
           current anti-retroviral regimens

        -  Subjects will be randomized to either a treatment or control arm

        -  Subjects randomized to the treatment arm will receive extended-release niacin (Niaspan
           ®) starting at 500 mg per night and titrated to a maximum tolerated dose (not exceeding
           1500 mg per night)

        -  Assess changes in FMD of the brachial artery using high-resolution ultrasound from
           baseline to week 12 (Total of 2 FMD assessments)

        -  Correlate changes in HDL with changes in FMD

      Hypothesis to be tested:

      Use of extended-release niacin will improve FMD among HIV-1 infected individuals with low HDL

        -  Following 12 weeks of therapy, subjects treated with extended-release niacin will show a
           8% improvement in FMD compared to controls

        -  There will be a positive correlation between changes in HDL with changes in FMD

      Specific Aim 2. To evaluate changes in lipid parameters, insulin sensitivity and
      cardiovascular risk markers with changes in FMD among the treatment and control arms

        -  Assess and compare changes in non-HDL lipid and lipoprotein parameters with changes in
           FMD among the two arms

        -  Assess and compare changes in insulin sensitivity by homeostasis model assessment (HOMA)
           with changes in FMD among the two arms

        -  Assess and compare changes in cardiovascular risk markers such as adhesion molecules and
           C-reactive protein with changes in FMD among the two arms

      Hypothesis to be tested:

      There will be a correlation between improvements in lipid, insulin sensitivity and
      cardiovascular risk markers and FMD in the extended niacin treatment arm

      SIGNIFICANCE and RATIONALE: Low HDL cholesterol levels elevate CAD risk independent of low
      density lipoprotein (LDL) cholesterol levels. In association with high triglyceride levels
      and with small LDL particle size, low HDL is part of the syndrome of atherogenic
      dyslipidemia. This form of dyslipidemia is characteristic of the underlying dyslipidemia
      found in HIV-infected subjects, likely represents the consequences of chronic inflammatory
      changes due to HIV, and contributes substantively to the CAD risk in this population even
      without the added risk from dyslipidemic antiretroviral medications. Primary CAD preventive
      modalities may be warranted for patients in the HIV population as well as in the general
      population who manifest this type of dyslipidemia. Niacin is currently the best medication
      available to elevate HDL cholesterol levels. Thus, using the novel technique of assessing
      flow-mediated dilatation of the brachial artery, a pilot project is proposed to assess
      whether the use of extended release niacin will lead to short term improvement in endothelial
      function. If successful, this study may lay the foundation for further studies into the
      potential use of niacin for prevention of CAD in patients who are particularly at risk for
      CAD due to low HDL cholesterol levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12</measure>
    <time_frame>Two time points (baseline and study week 12)</time_frame>
    <description>Brachial arterial flow-mediated dilation (FMD), assessed by high-resolution ultrasonography, reflects endothelium-dependent vasodilator function. The primary outcome is the change in FMD from baseline to study week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow Mediated Vasodilation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Flow mediated vasodilation is a marker of endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12</measure>
    <time_frame>Two time points (baseline and study week 12)</time_frame>
    <description>HDL, often referred to &quot;Good cholesterol levels&quot;, will be obtained in both arms. HDL is a marker of coronary heart disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV Infections</condition>
  <condition>Dyslipidemia</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Active Drug (extended release niacin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extended release niacin</intervention_name>
    <description>Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.</description>
    <arm_group_label>Active Drug (extended release niacin)</arm_group_label>
    <other_name>Niaspan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Documented HIV infection

          -  Subjects must have taken HAART 6 months prior to study entry and must be on stable
             HAART (no dose change to antiretroviral medications) for at least 30 days immediately
             prior to study entry

          -  HDL &lt; 40 mg/dL • LDL &lt; 130 mg/dL

          -  All subjects with reproductive potential should utilize adequate contraception for the
             duration of this study and for at least 12 weeks following permanent discontinuation
             of study treatment. Acceptable methods include male condom, female condom, diaphragm,
             or intra-uterine device (IUD)

        Exclusion Criteria:

          -  Known cardiac disease

          -  Arrhythmia

          -  History of angina

          -  Uncontrolled hypertension

          -  Pregnancy

          -  Breast-feeding

          -  Medication known to influence vasodilatation such as nitrates, metformin,
             pioglitazone, and rosiglitazone

          -  Heavy use of vitamin supplements

          -  Diagnosis of diabetes mellitus

          -  Treatment with lipid-lowering drugs within 6 weeks prior to study

          -  Hemoglobin &lt;9.0 mg/dL

          -  Absolute neutrophil count &lt;750 cells/mm3

          -  Platelet count &lt;75,000 platelets/ mm3

          -  Alanine aminotransferase (ALT or SGOT)/ aspartate aminotransferase (AST or SGPT) /
             alkaline phosphatase &gt; 2.5 x upper limit of normal (ULN)

          -  Creatinine &gt;1.5 x ULN

          -  Individuals with an infection or other medical illness requiring hospitalization
             within 14 days prior to study entry

          -  Individuals who have active alcohol or drug abuse which, in the investigator's
             opinion, is sufficient to prevent adequate compliance with study therapy and
             evaluations

          -  Prior history of hypersensitivity reaction to niacin or any other component of the
             study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominic C Chow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawaii - Hawaii Center for AIDS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Hawaii - Hawaii Center for AIDS</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chow DC, Stein JH, Seto TB, Mitchell C, Sriratanaviriyakul N, Grandinetti A, Gerschenson M, Shiramizu B, Souza S, Shikuma C. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS. 2010 Apr 24;24(7):1019-23. doi: 10.1097/QAD.0b013e3283383016.</citation>
    <PMID>20216298</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <results_first_submitted>August 14, 2011</results_first_submitted>
  <results_first_submitted_qc>November 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2012</results_first_posted>
  <last_update_submitted>November 19, 2012</last_update_submitted>
  <last_update_submitted_qc>November 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hawaii</investigator_affiliation>
    <investigator_full_name>Dominic Chow</investigator_full_name>
    <investigator_title>Associate Professor of Medicine and Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>Low high density lipoprotein</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Flow-mediated vasodilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was through the University of Hawaii, Hawaii Center for AIDS</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Drug (Extended Release Niacin)</title>
          <description>Subjects in this arm will be given 12 weeks of extended release niacin</description>
        </group>
        <group group_id="P2">
          <title>Observation</title>
          <description>Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Drug (Extended Release Niacin)</title>
          <description>Subjects in this arm will be given 12 weeks of extended release niacin</description>
        </group>
        <group group_id="B2">
          <title>Observation</title>
          <description>Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.96" spread="11.60"/>
                    <measurement group_id="B2" value="47.72" spread="10.81"/>
                    <measurement group_id="B3" value="48.84" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12</title>
        <description>Brachial arterial flow-mediated dilation (FMD), assessed by high-resolution ultrasonography, reflects endothelium-dependent vasodilator function. The primary outcome is the change in FMD from baseline to study week 12.</description>
        <time_frame>Two time points (baseline and study week 12)</time_frame>
        <population>HIV infected patients with HDL-C &lt; 40</population>
        <group_list>
          <group group_id="O1">
            <title>Extended Release Niacin</title>
            <description>HIV infected individuals receiving extended release niacin</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Flow-mediated Vasodilation (FMD) From Baseline to Study Week 12</title>
          <description>Brachial arterial flow-mediated dilation (FMD), assessed by high-resolution ultrasonography, reflects endothelium-dependent vasodilator function. The primary outcome is the change in FMD from baseline to study week 12.</description>
          <population>HIV infected patients with HDL-C &lt; 40</population>
          <units>percentage change in FMD</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.36" lower_limit="4.85" upper_limit="7.87"/>
                    <measurement group_id="O2" value="2.73" lower_limit="0.95" upper_limit="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12</title>
        <description>HDL, often referred to &quot;Good cholesterol levels&quot;, will be obtained in both arms. HDL is a marker of coronary heart disease.</description>
        <time_frame>Two time points (baseline and study week 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug (Extended Release Niacin)</title>
            <description>Subjects in this arm will be given 12 weeks of extended release niacin</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin</description>
          </group>
        </group_list>
        <measure>
          <title>High-density Lipoprotein Cholesterol (HDL) Change From Baseline to Study Week 12</title>
          <description>HDL, often referred to &quot;Good cholesterol levels&quot;, will be obtained in both arms. HDL is a marker of coronary heart disease.</description>
          <units>mg/dl</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" lower_limit="39.3" upper_limit="43.5"/>
                    <measurement group_id="O2" value="27.0" lower_limit="24.0" upper_limit="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flow Mediated Vasodilation</title>
        <description>Flow mediated vasodilation is a marker of endothelial function</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Drug (Extended Release Niacin)</title>
            <description>Subjects in this arm will be given 12 weeks of extended release niacin</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin</description>
          </group>
        </group_list>
        <measure>
          <title>Flow Mediated Vasodilation</title>
          <description>Flow mediated vasodilation is a marker of endothelial function</description>
          <units>percentage change in FMD</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" lower_limit="4.46" upper_limit="8.32"/>
                    <measurement group_id="O2" value="3.25" lower_limit="1.95" upper_limit="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL</title>
        <time_frame>12 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Drug (Extended Release Niacin)</title>
          <description>Subjects in this arm will be given 12 weeks of extended release niacin</description>
        </group>
        <group group_id="E2">
          <title>Observation</title>
          <description>Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size
Un-blinded pilot study
Increase in HDL was less than predicted in a non-HIV infected population</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dominic Chow</name_or_title>
      <organization>University of Hawaii at Manoa</organization>
      <phone>(808)737-2751</phone>
      <email>dominicc@hawaii.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

